Our in vivo result is consistent with an in vitro result reported by Nyati et al. They showed that DHP-2, a ZAK specific inhibitor, inhibited TGF-β-mediated cell migration in breast cancer cell line MDA-231–183337. The gene discussed is TGFB1; the disease is breast carcinoma.